| pubmed-article:16716972 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16716972 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:16716972 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:16716972 | lifeskim:mentions | umls-concept:C0015733 | lld:lifeskim |
| pubmed-article:16716972 | lifeskim:mentions | umls-concept:C0021390 | lld:lifeskim |
| pubmed-article:16716972 | lifeskim:mentions | umls-concept:C0017710 | lld:lifeskim |
| pubmed-article:16716972 | lifeskim:mentions | umls-concept:C0950624 | lld:lifeskim |
| pubmed-article:16716972 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:16716972 | pubmed:dateCreated | 2006-5-23 | lld:pubmed |
| pubmed-article:16716972 | pubmed:abstractText | Fecal calprotectin is a promising marker for the assessment of gastrointestinal inflammation. Fecal calprotectin levels were followed-up in children with inflammatory bowel disease (IBD) who were introduced to glucocorticoid therapy. The aim of this study was to assess whether the changes in fecal calprotectin levels reflect therapeutic responses. | lld:pubmed |
| pubmed-article:16716972 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16716972 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16716972 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16716972 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16716972 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16716972 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16716972 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16716972 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:16716972 | pubmed:issn | 0036-5521 | lld:pubmed |
| pubmed-article:16716972 | pubmed:author | pubmed-author:SavilahtiErkk... | lld:pubmed |
| pubmed-article:16716972 | pubmed:author | pubmed-author:RaivioTaneliT | lld:pubmed |
| pubmed-article:16716972 | pubmed:author | pubmed-author:LindahlHarryH | lld:pubmed |
| pubmed-article:16716972 | pubmed:author | pubmed-author:KolhoKaija-Le... | lld:pubmed |
| pubmed-article:16716972 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16716972 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:16716972 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16716972 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16716972 | pubmed:pagination | 720-5 | lld:pubmed |
| pubmed-article:16716972 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:meshHeading | pubmed-meshheading:16716972... | lld:pubmed |
| pubmed-article:16716972 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16716972 | pubmed:articleTitle | Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. | lld:pubmed |
| pubmed-article:16716972 | pubmed:affiliation | Hospital for Children and Adolescents, University of Helsinki, Finland. kaija-leena.kolho@helsinki.fi | lld:pubmed |
| pubmed-article:16716972 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16716972 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16716972 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16716972 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16716972 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16716972 | lld:pubmed |
